Scope, Duration, and Significance of Use.

4 min read

Section 5. Scope, Duration, and Significance of Use.

The legislative history of the Controlled Substances Act indicates that scheduling decisions must include consideration of the costs of law enforcement attendant to a drug or substance’s scheduling, as well as a consideration of the impact of such law enforcement on the young.

The absolute yet unenforceable schedule I prohibition contributes to an unfavorable set and setting accompanying school-age access and exposure to marijuana. Not only are students provided access to marijuana, they are also grossly uninformed and misled about the substance and its use.

Adherence to the polarized and unscientific ‘use = abuse’ model obstructs the development of effective, research based policy and drug-abuse prevention programs; this restrains progress in protecting school-age youths from the dangers presented by all drugs, legal or not.

Marijuana prohibition makes criminals out of patients who use marijuana for legitimate therapeutic purposes, and forces patients to choose between honoring the law and honoring their own health.

The absolute yet unenforceable schedule I prohibition creates tremendous ethical problems for physicians and health-care-providers, professionals well-aware of the widening gap between existing governmental policies and the developing support for marijuana’s therapeutic potential in scientific and medical literature, and professionals who are seemingly instructed by law to discourage their patients from using marijuana even if such use has obvious therapeutic benefits.

The failure of the Department of Health and Human Services, and of the National Institute on Drug Abuse specifically, to address this widening breach between recent research about marijuana and the findings required to sustain marijuana’s schedule I status unfairly and inappropriately makes our federal law enforcement officials, particularly officials of the Drug Enforcement Administration, appear to be heartless, insensitive, self-serving idiots.

The federal failure to reconcile marijuana’s schedule I status with contemporary medical and scientific evidence places an unfair and expensive burden on state criminal justice agencies and their limited budgets.

Marijuana’s schedule I status and the high priority it places on domestic and international marijuana eradication has the unintended effect of transforming domestic law enforcement activity into a massive market and price support mechanism for entrepreneurs here and abroad.

Marijuana’s schedule I status mandates high priority for domestic marijuana eradication efforts; the nearly impossible task presented to law enforcement results in extreme measures and increasing federalization of local and state judicial authority.

One of the results of the DEA’s domestic marijuana eradication program is that in the mid 1990’s domestic marijuana cultivation is now so extensive and decentralized that the DEA admits they can no longer estimate how much marijuana is grown in the United States. If they have lost hope of even estimating how much is grown, they have abandoned hope of ever eliminating marijuana cultivation in the United States, and of ever enforcing marijuana’s schedule I status as a completely prohibited substance. The purpose of schedule I is to regulate the manufacture of drugs and substances with the highest potential for abuse; without control of domestic marijuana cultivation such regulation is impossible.

References Cited in Section 5.

Abood, M.E., and Martin, B.R., , “Neurobiology of Marijuana Abuse,” Trends in Pharmacological Sciences 13:201-206, 1992.

Aldrich, M., Mikuriya, T., et al., Fiscal Savings In California Marijuana Law Enforcement, 1976 – 1985 Attributable to the Moscone Act of 1976, (Berkeley, CA: Medi-Comp Press,) 1986.

Aldrich, M.R., Mikuriya, T., “Savings in California, Marijuana Law Enforcement Costs Attributable to the Moscone Act of 1976–A Summary.” Journal of Psychoactive Drugs. Vol. 20(1):75-81, 1988.

Alliance for Cannabis Therapeutics v. Drug Enforcement Administration. 15 F3d 1131 (1994, App DC)

Brady, J.V., “What’s a Radical Behaviorist Like You Doing in a Nice Pharmacology Club like CPDD?” In: Problems of Drug Dependence, 1992. Proceedings of the 54th Annual Scientific Meeting, The Committee on Problems of Drug Dependence, Inc. Harris, L. (ed), National Institute on Drug Abuse Research Monograph 132. (Washington, D.C.: U.S. Govt. Print. Off.,) 1993. pg 19 -28.

Brownell, G., “Marijuana and the Law in California: A Historical and Political Overview.” Journal of Psychoactive Drugs. Vol. 20(1):71-74, 1988.

Chalsma, A., Boyum, D., Marijuana Situation Assessment. (Washington, D.C.: Office of National Drug Control Policy,) 1994.

Consroe, P., Laguna, J. et al., “Controlled Clinical Trial of Cannabidiol in Huntington’s Disease.” Pharmacology, Biochemistry, & Behavior. 40:701-708, 1991.

Gettman, J., Cannabis Suppression and Marijuana Crop Value. (Washington, D.C.: National Organization for the Reform of Marijuana Laws,) 1993.

Grinspoon, L. Marihuana, The Forbidden Medicine. (New Haven: Yale University Press,) 1993.

Herkenham, M., “Cannabinoid Receptor Localization in Brain: Relationship to Motor and Reward Systems,” In P.W. Kalivas and H.H. Samson (eds.), The Neurobiology of Drug and Alcohol Addiction. Annals of the American Academy of Sciences. 654:19-32, 1992.

Herkenham, M., Lynn, A.B., et al., “Cannabinoid Receptor Localization in Brain,” Proceedings of the National Academy of Sciences, 87:1932-1936, 1990.

Hollister, L.E. “Health Aspects of Cannabis”, Pharmacological Reviews, 38(1):1-20. 1986.

Mechoulam, R., , “Interview with Professor Raphael Mechoulam, Codiscoverer of THC”, The International Journal of the Addictions, 21(4&5), 579-587, 1986. (The interview was conducted by Stanley Einstein in Jerusalem on January 14, 1985.)

National Drug Enforcement Policy Board, “Analysis of the Domestic Cannabis Problem and The Federal Response, Staff Report” (Washington, D.C.: NDEPB,) 1986.

National Drug Enforcement Policy Board, “National and International Drug Law Enforcement Strategy” (Washington, D.C.: NDEPB,) 1987.

National Drug Enforcement Policy Board, “Federal Drug Enforcement Progress Report, 1984-1985” (Washington, D.C.: NDEPB,) 1986.

National Narcotics Intelligence Consumers Committee, “1989 Narcotics Intelligence Estimate” (Washington, D.C.:DEA,) 1990.

National Narcotics Intelligence Consumers Committee, “1990 Narcotics Intelligence Estimate” (Washington, D.C.:DEA,) 1991.

National Narcotics Intelligence Consumers Committee, “1991 Narcotics Intelligence Estimate” (Washington, D.C.:DEA,) 1992.

Rhodes, W., Scheiman, P., et al., What America’s Users Spend on Illegal Drugs, 1988-1993. (Washington, D.C.: Office of National Drug Control Policy,) 1995. Prepared by Abt Associates under contract no. DC2C04.

Shafer, R., Commission on Marihuana and Drug Abuse, (1972) Marihuana, a signal of misunderstanding; first report of the National Commission on Marihuana and Drug Abuse, March 1972. (Washington, D.C.: U.S. Govt. Print. Off.,) 1972.

Shafer, R., Commission on Marihuana and Drug Abuse, (1973) Drug Use In America: Problem In Perspective, second report of the National Commission on Marihuana and Drug Abuse, Vol. I. March 1973. (Washington, D.C.: U.S. Govt. Print. Off.,) 1973.

Swann, N., “Marijuana’s Natural Counterpart Discovered.” NIDA Notes. September/October 1993. pg. 8.

U.S. Code Congressional and Administrative News. 91st Congress — Second Session, 1970. Vol. 3. Legislative History. Comprehensive Drug Abuse Prevention and Control Act of 1970 [P.L. 91-513]. pg. 4566 – 4657.

U.S. Congress, Office of Technology Assessment (1994) Technologies for Understanding and Preventing Substance Abuse and Addiction, OTA-EHR-597 (Washington, DC: U.S. Government Printing Office,) September 1994.

U.S. Department of Justice, Drug Enforcement Administration, Cannabis Investigation Section. 1982 Domestic Cannabis Eradication/Suppression Program. (Washington, D.C.:DEA,) 1983.

U.S. Department of Justice, Drug Enforcement Administration, Cannabis Investigation Section. 1983 Domestic Cannabis Eradication/Suppression Program. (Washington, D.C.:DEA,) 1984.

U.S. Department of Justice, Drug Enforcement Administration, Cannabis Investigation Section. 1984 Domestic Cannabis Eradication/Suppression Program. (Washington, D.C.:DEA,) 1985.

U.S. Department of Justice, Drug Enforcement Administration, Cannabis Investigation Section. 1985 Domestic Cannabis Eradication/Suppression Program. (Washington, D.C.:DEA,) 1986.

U.S. Department of Justice, Drug Enforcement Administration, Cannabis Investigation Section. 1986 Domestic Cannabis Eradication/Suppression Program. (Washington, D.C.:DEA,) 1987.

U.S. Department of Justice, Drug Enforcement Administration, Cannabis Investigation Section. 1987 Domestic Cannabis Eradication/Suppression Program. (Washington, D.C.:DEA,) 1988.

U.S. Department of Justice, Drug Enforcement Administration, Cannabis Investigation Section. 1988 Domestic Cannabis Eradication/Suppression Program. (Washington, D.C.:DEA,) 1989.

U.S. Department of Justice, Drug Enforcement Administration, Cannabis Investigation Section. 1989 Domestic Cannabis Eradication/Suppression Program. (Washington, D.C.:DEA,) 1990.

U.S. Department of Justice, Drug Enforcement Administration, Cannabis Investigation Section. 1990 Domestic Cannabis Eradication/Suppression Program. (Washington, D.C.:DEA,) 1991.

U.S. Department of Justice, Drug Enforcement Administration, Cannabis Investigation Section. 1991 Domestic Cannabis Eradication/Suppression Program. (Washington, D.C.:DEA,) December 1991.

U.S. Department of Justice, Drug Enforcement Administration, Cannabis Investigation Section. 1992 Domestic Cannabis Eradication/Suppression Program. (Washington, D.C.:DEA,) 1993.

U.S. Department of Justice, Drug Enforcement Administration, Docket No. 86-22. Marijuana Scheduling Petition, Denial of Petition. 54 Fed. Reg. 53,787 (1989)

U.S. Department of Justice, Drug Enforcement Administration, Docket No. 86-22. Marijuana Scheduling Petition, Denial of Petition; Remand. 57 Fed. Reg. 10,499 (1992)

Zinberg, N. Drug, Set, and Setting. (New Haven: Yale University Press,) 1984.